Stock info Schott Pharma | Filter Basic-Info
Stock: Schott Pharma (Germany small caps)
| Last Price | 21.40 | Max Price | 25.50 |
| Min Price | 4.97 | 1 Year return | -27.16 |
| Avg. Target | 19.33 | Expected Return | -11.52 % |
| Sector | Health Care | Subsector | Pharmaceuticals |
| Sell | 0 | Rating |
|
| Hold | 1 | Concensus |
 
|
| Buy | 2 |
Loading...
Contact info:Country: Germany
Sector Review Schott Pharma
Loading...
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 0 | 474,848 | 0.00 % |
| 2020 | 584 | 469,560 | 0.12 % |
| 2021 | 649 | 566,739 | 0.11 % |
| 2022 | 821 | 640,095 | 0.13 % |
| 2023 | 899 | 590,728 | 0.15 % |
Advice Schott Pharma
| Date Label | Bank Label | Stock Label | Advice Label | Price Label | Diff Label |
|---|---|---|---|---|---|
| August 12, 2026 | RBC Capital Markets | Schott Pharma | Buy | 21.00 | -4.05 % |
| July 06, 2026 | Deutsche Bank | Schott Pharma | Buy | 22.00 | 0.68 % |
| December 08, 2025 | Barclays | Schott Pharma | Hold | 15.00 | -45.67 % |
| May 17, 2026 | Deutsche Bank | Schott Pharma | Hold | 16.00 | -36.56 % |
| November 03, 2025 | DZ Bank | Schott Pharma | Buy | 24.00 | -4.17 % |
| August 12, 2025 | Jefferies & Co. | Schott Pharma | Hold | 24.30 | 8.23 % |
| November 28, 2024 | UBS | Schott Pharma | Hold | 32.60 | 42.02 % |
| November 28, 2024 | Barclays | Schott Pharma | Buy | 27.00 | 30.00 % |
| September 02, 2024 | Jefferies & Co. | Schott Pharma | Hold | 31.80 | 28.62 % |
| September 01, 2024 | UBS | Schott Pharma | Hold | 32.60 | 27.91 % |
| July 09, 2024 | UBS | Schott Pharma | Buy | 32.60 | 12.58 % |
| July 09, 2024 | Berenberg | Schott Pharma | Buy | 32.00 | 10.94 % |
| July 09, 2024 | Barclays | Schott Pharma | Buy | 30.00 | 5.00 % |
| July 04, 2024 | Jefferies & Co. | Schott Pharma | Hold | 32.70 | 12.84 % |
News Schott Pharma
No Records Found
Annual reports Schott Pharma
No Records Found
Profile Schott Pharma
No Records Found
Results Schott Pharma
| Results |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Revenue |
|
|
|
|
|
| Costs |
|
|
|
|
|
| Profit |
|
|
|
|
|
| Margin of profit |
|
|
|
|
|
| ROI |
|
|
|
|
|
Balance Schott Pharma
| Balance |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Equity |
|
|
|
|
|
| Debt |
|
|
|
|
|
| Total assets |
|
|
|
|
|
| Solvency |
|
|
|
|
|
| Cash |
|
|
|
|
|
| Cashflow |
|
|
|
|
|
| Employees |
|
|
|
|
|
| Revenue per employee |
|
|
|
|
|
| Cashflow / Debt |
|
|
|
|
|
Details Schott Pharma
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
0.0
|
0.0
|
0.0
|
0.0
|
21.85
|
| Eps |
0.0
|
0.0
|
0.0
|
0.0
|
0.51
|
| Price/earnings-ratio |
0.0
|
0.0
|
0.0
|
0.0
|
42.84
|
| Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
| Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Book value |
0.0
|
0.0
|
0.0
|
0.0
|
2.09
|
| Market to book |
0.0
|
0.0
|
0.0
|
0.0
|
0.10
|
| Cashflow per stock |
0.0
|
0.0
|
0.0
|
0.0
|
0.69
|
| Stocks |
0
|
0
|
0
|
0
|
151
|
| Market Cap |
0.00
|
0.00
|
0.00
|
0.00
|
3.290.94
|
Dividend Schott Pharma
Price info Schott Pharma
|
Date
|
Price
|
|---|---|
|
12 Nov 2026
|
21.40
|
|
10 Nov 2026
|
21.25
|
|
06 Nov 2026
|
21.85
|
|
05 Nov 2026
|
23.35
|
|
04 Nov 2026
|
24.00
|
|
03 Nov 2026
|
25.05
|
|
02 Nov 2026
|
25.00
|
|
30 Oct 2026
|
25.30
|
|
29 Oct 2026
|
25.25
|
|
28 Oct 2026
|
25.50
|
|
27 Oct 2026
|
25.50
|
|
13 Oct 2026
|
24.10
|
|
09 Oct 2026
|
24.65
|
|
08 Oct 2026
|
25.15
|
|
06 Oct 2026
|
24.70
|
|
17 Sep 2026
|
23.05
|
|
15 Sep 2026
|
22.60
|
|
14 Sep 2026
|
23.05
|
|
28 Aug 2026
|
23.45
|
|
11 Aug 2026
|
22.30
|
|
07 Aug 2026
|
21.90
|
|
06 Aug 2026
|
22.15
|
|
28 Jul 2026
|
20.85
|
|
14 Jul 2026
|
20.75
|
|
10 Jul 2026
|
20.00
|
|
30 Jun 2026
|
17.16
|
|
23 May 2026
|
7.15
|
|
01 May 2026
|
7.54
|
|
28 Apr 2026
|
7.15
|
|
21 Apr 2026
|
6.04
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x |
©2026 ValueSpectrum. All Rights Reserved
Developed and maintained by 